A New Laboratory Research and Testing Group on LinkedIn
Join us on the new LinkedIn Laboratory Research & Testing group. This group has been created to learn and share and help you develop new, R&D intensive analytical and bioanalytical approaches to expedite the process of bringing new products to market. We aspire to create an environment where the brightest academic ideas can be efficiently integrated into a highly regulated drug development framework.
The pharmaceutical industry is facing a crisis. Looming patent expirations, industry consolidation, increased regulatory agency scrutiny and the worst economic recession and credit crisis in many generations have combined to stall new drug development. The industry is also migrating away from blockbuster drugs that target larger populations toward tailored drugs that target smaller segments of the population.
This has caused companies to avoid new laboratory testing methodologies, preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals.
Furthermore, academic research-based modifications to established laboratory testing procedures in drug development are severely restricted because of the concern over triggering costly adjustments to the established regulatory framework.
A more flexible and R&D intensive approach is clearly needed by both emerging and established pharmaceutical companies, which also takes into account recent advancements in genetic research.
We invite you to join our group and openly welcome ideas, insights and comments that will help you develop better methodologies and improve the probability of bringing your new products to market.